Ionis Pharmaceuticals has enlisted the help of Suzhou Ribo Life Science to help it bring three of its RNA-based drugs to the Chinese market.

Allergan has wasted little time in testing out its new fatty liver candidate that it got in the potentially $1.7 billion buyout of Tobira last year as it pens…

It doesn’t rain, but it pours in April for OncoMed: Last week, it had a double dose of bad news when it revealed that its Celgene-partnered lead asset…

Eli Lilly and Incyte were expecting an approval this weekend from the FDA for their blockbuster-in-waiting arthritis candidate baricitinib, but today announced…

Bristol-Myers Squibb has offloaded two neurodegenerative disease programs to Biogen and Roche in separate deals.

Peter Thiel’s Breakout Labs continues apace as the nonprofit seed-stage fund has injected more cash into a host of biotechs, labs and startups.

SV Health Investors (formerly SV Life Sciences) has closed its sixth fund, hitting its target of $400 million, as the firm itself also registers a numbers…

Microbiome biotech Finch Therapeutics has signed a pact with perennial U.S. life sciences dealmaker Takeda to jointly work on FIN-524, a microbial cocktail for…

Viracta Therapeutics has closed a $18.4 million Series B round, with lead investor NantKwest also setting up a new midstage licensing deal.

Deals